Â鶹ѧÉú¾«Æ·°æ

Kathleen C. Kerrigan
Rating: 4.9 of 5
( out of 183 reviews )

Kathleen C. Kerrigan, DO

Languages spoken: English

Clinical Locations

Primary Location

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000

  • Dr. Katie Kerrigan is an Associate Professor in the Division of Oncology, Department of Internal Medicine at the University of Utah and an investigator at Huntsman Cancer Institute. She specializes in cancers of the head and neck, thyroid, and lungs, and serves as principal investigator on multiple Phase I-III clinical trials in these areas.

    Dr. Kerrigan co-leads the Head and Neck Clinical Trials Research Group and is an active member of several institutional and national committees, including the HCI Data Safety Monitoring Committee and the Patient-Reported Outcomes (PRO) Workgroup within the National Comprehensive Cancer Network (NCCN) EHR Oncology Advisory Group. She also serves as a co-advisor for the University of Utah School of Medicine Oncology Interest Group and plays a key role in strengthening clinical connections with Huntsman Cancer Institute's affiliate partners.

    Since 2022, Dr. Kerrigan has provided both in-person and telehealth oncology care to patients in rural and frontier regions of Wyoming (St. John's Health) and Montana (St. Peter's Health). She is deeply committed to expanding access to high-quality cancer care and clinical trials across the Intermountain West. Her research focuses on early - and late-phase clinical trials and drug development.

    Dr. Kerrigan joined the University of Utah in 20217 after completing her Hematology-Oncology fellowship at the University of Utah and Huntsman Cancer Institute, where she received the Joseph Quagliana Award for her research in lung cancer and patient-reported outcomes (PROs). She completed her residency in Internal Medicine at The Ohio State University and earned her medical degree from the Ohio University HEritage College of Osteopathic Medicine.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Osteopathic Medical Examiners

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 183 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    September 20, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Kerrigan is an excellent physician. She is knowledgeable, attentive, collegial, caring, and cordial. Look no further if you require her expertise.

    September 19, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 4 out of 5

    Dr. Kerrigan is a very caring individual. It is always a pleasure to see her. I am glad that she is my primary care physician.

    September 18, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Kerrigan still has that ¿new doctor smell!¿ In other words, her enthusiasm to take care of her patients is very evident during my interactions with her. She didn't rush or act put out by my questions or observations. Very refreshing personality and her commitment to do her very best is evident!

    September 14, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Karrigan provided me with the results she had available in an easy to understand fashion. She was not able to talk to me re my chest CT because the results had not been provided at the time of the appointment. The results indicated a possible issue that would have been discussed if the results of the CT were available at the appointment. I have not heard from anyone about the results. I trust I will be contacted to discuss the results in a timely manner.

    September 06, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Kerrigan takes her time with you, asks pertinent questions and gives good thoughtful feedback.

    August 29, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    When Dr. Kerrigan greeted me with a handshake and a smile... I felt myself relax. I just knew I was so lucky to be her patient.

    August 23, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Kerrigan is a fantastic care provider incredibly knowledgeable, wonderful bedside manner excellent listener, outstanding

    August 15, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Kerrigan is kind, caring and thorough. She listens to any concerns I have and takes action when it is necessary. My wife and I love Dr Kerrigan!

    August 09, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    She takes a broad holistic approach to my needs and genuinely cares

    See More Patient Comments

  • Dr. Katie Kerrigan is an Associate Professor in the Division of Oncology, Department of Internal Medicine at the University of Utah and an investigator at Huntsman Cancer Institute. She specializes in cancers of the head and neck, thyroid, and lungs, and serves as principal investigator on multiple Phase I-III clinical trials in these areas.

    Dr. Kerrigan co-leads the Head and Neck Clinical Trials Research Group and is an active member of several institutional and national committees, including the HCI Data Safety Monitoring Committee and the Patient-Reported Outcomes (PRO) Workgroup within the National Comprehensive Cancer Network (NCCN) EHR Oncology Advisory Group. She also serves as a co-advisor for the University of Utah School of Medicine Oncology Interest Group and plays a key role in strengthening clinical connections with Huntsman Cancer Institute's affiliate partners.

    Since 2022, Dr. Kerrigan has provided both in-person and telehealth oncology care to patients in rural and frontier regions of Wyoming (St. John's Health) and Montana (St. Peter's Health). She is deeply committed to expanding access to high-quality cancer care and clinical trials across the Intermountain West. Her research focuses on early - and late-phase clinical trials and drug development.

    Dr. Kerrigan joined the University of Utah in 20217 after completing her Hematology-Oncology fellowship at the University of Utah and Huntsman Cancer Institute, where she received the Joseph Quagliana Award for her research in lung cancer and patient-reported outcomes (PROs). She completed her residency in Internal Medicine at The Ohio State University and earned her medical degree from the Ohio University HEritage College of Osteopathic Medicine.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Osteopathic Medical Examiners

    Education history

    Fellowship Hematology & Oncology - University of Utah School of Medicine Chief Fellow
    Fellowship Hematology & Oncology - University of Utah School of Medicine Fellow
    Research Fellow Internal Medicine - Ohio State University Resident
    Fellowship Research and Scholarly Advancement Fellowship (RSAF) program - Ohio University Heritage College of Osteopathic Medicine Research Fellow
    Doctoral Training Osteopathic Medicine - Ohio University Heritage College of Osteopathic Medicine D.O.
    Undergraduate Ohio State University B.S.

    Selected Publications

    Journal Article

    1. Jo Y, Puri S, Haaland B, Coletta AM, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley WL (2024). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer, 26(1), 29-38. ()
    2. Rock CB, Hutten RJ, Weil CR, Lloyd S, Kerrigan KC, Cannon RB, Hitchcock YJ (2022). Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head Neck, 45(2), 431-438. ()
    3. McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D (2022). Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf), 96(5), 734-742. ()
    4. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. ()
    5. Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3). ()
    6. Stetson PD, McCleary NJ, Osterman T, Ramchandran K, Tevaarwerk A, Wong T, Sugalski JM, Akerley W, Mercurio A, Zachariah FJ, Yamzon J, Stillman RC, Gabriel PE, Heinrichs T, Kerrigan K, Patel SB, Gilbert SM, Weiss E (2022). Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. J Natl Compr Canc Netw, 1-6. ()
    7. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. ()
    8. Kerrigan K, Chan J, Vagher J, Kohlmann W, Naumer A, Anson J, Low S, Schiffman J, Maese L (2021). Lung Cancer in Li Fraumeni Syndrome. . JCO Precis Oncol, 23(5).
    9. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer.
    10. Kerrigan K, Patel SB, Haaland B, Ose D, Chalmers AW, Haydell T, Meropol NJ, Akerley WL (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. 16(4), 313-323.
    11. Kerrigan K, Shoben A, Otterson G (2016). Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer, 17(6), 523-527. ()
    12. Kerrigan KOtterson G (2016). Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit Setting. Am J Respir Crit Care Med.

    Review

    1. Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123. ()
    2. Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki M, Pinato DJ, Puri S (2021). The Role of Gut Microbiome in Modulating Response to Immune Checkpoint Inhibitor Therapy in Cancer. [Review]. Ann Transl Med.

    Case Report

    1. Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 26(1), 224-227. ()
    2. Griswold CR, Kerrigan K, Patel SB (2019). Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. Case Rep Oncol, 12(3), 866-871. ()

    Abstract

    1. Owonikok TK, Elliot A, Dwivedi B, Ivanov A, Sica G, Kerrigan K, et al (2022). Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC) [Abstract].
    2. Russell J, Kerrigan K, Yang D (2022). Circulating tumor DNA profiling and serial analysis in salivary gland carcinomas reveal unique mutational subsets and actionable alterations [Abstract].
    3. Kerrigan K, Puri S, Sinnott JHaaland B, Akerley W, Patel SB (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis. [Abstract]. 16(3), 89.05.
    4. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. [Abstract]. 16(3 S122-123), OA09.05.
    5. Kerrigan K, Chipman J, Jo Y, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel SB (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy. [Abstract]. 16(3, S199), FP05.01.
    6. Puri S, Patel S, Chalmers A, Kerrigan K, Cannon L, George S, Boucher K, Akerley W (2021). Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC [Abstract]. 16(3, S344), P15.02.
    7. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-308.
    8. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), P1.01-35.

    Video/Film/CD/Web/Podcast

    1. Kerrigan K (2019). Incorporation PROs Can Improve Patient Care and Outcomes [Web]. OncLive Oncology Fellows Magazine.